CHDH and breast carcinoma: A 5-gene assay was also developed quantifying the expression of CHDH, HOXB13, IL17BR, MIB1 and MKI67 to identify a subgroup of early stage estrogen receptor–positive breast cancer patients with very poor outcome despite endocrine therapy [19].